L. Teixeira

发表

18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis

D. Groheux, A. Martineau, P. Merlet, 2017, Breast Cancer Research.

Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients

D. Groheux, A. Martineau, P. Merlet, 2017, European Journal of Nuclear Medicine and Molecular Imaging.

Ductal carcinoma in situ (DCIS) treated by mastectomy, or local excision with or without radiotherapy: A monocentric, retrospective study of 608 women.

M. Espié, R. Porcher, A. de Roquancourt, 2016, Breast.

Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.

P. Fasching, F. Couch, K. Gelmon, 2021, European journal of cancer.

Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2− Breast Cancer

M. Hatt, D. Visvikis, M. Majdoub, 2015, The Journal of Nuclear Medicine.

Efficacy of FOLFOX4 as adjuvant therapy in stage II colon cancer (CC): A new analysis of the MOSAIC trial according to risk factors.

C. Tournigand, T. Hickish, C. Boni, 2010 .

First French Pilot Quality Assessment of the EndoPredict Test for Early Luminal Breast Carcinoma.

I. Bièche, P. Lamy, P. de Cremoux, 2018, Anticancer research.

Multi-modal Imaging Breast Cancer Detection: A Technological Review

L. Teixeira, Hélder Oliveira, J. Teixeira, 2015 .

Prognostic impact of ESR1 mutations in ER+ HER2- MBC patients prior treated with first line AI and palbociclib: An exploratory analysis of the PADA-1 trial.

I. Bièche, F. Clatot, J. Lemonnier, 2020 .

Intraoperative Radiotherapy for Breast Cancer in Elderly Women.

M. Espié, L. Quéro, S. Giacchetti, 2021, Clinical breast cancer.

10-Year follow-up of 621 patients treated using high-dose rate brachytherapy as ambulatory boost technique in conservative breast cancer treatment.

M. Espié, L. Quéro, S. Guillerm, 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.

I. Bièche, F. Clatot, F. André, 2022, The Lancet. Oncology.

Squamous-cell carcinoma of the anal canal: room for improvement with targeted therapy.

C. Tournigand, P. Hoff, A. de Gramont, 2012, Clinics and research in hepatology and gastroenterology.

FOLFOX4 as adjuvant therapy in elderly patients (pts) with colon cancer (CC): Subgroup analysis of the MOSAIC trial.

C. Tournigand, T. Hickish, C. Boni, 2010 .

Efficacy of SARS-CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses

E. Vicaut, C. Charpentier, G. Zalcman, 2021, medRxiv.

Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants

K. Pogoda, F. Clatot, M. Dieci, 2021, NPJ breast cancer.

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.

W. Scheithauer, J. Tabernero, V. Heinemann, 2015, Journal of the National Cancer Institute.

[Targeted agents in the treatment of lung cancer].

J. Trédaniel, L. Staudacher, R. Cohen, 2012, Pathologie-biologie.

Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations.

K. Pogoda, F. Clatot, M. Dieci, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nonpalpable breast lesions: impact of a second-opinion review at a breast unit on BI-RADS classification

M. Espié, S. Giacchetti, C. Cuvier, 2021, European Radiology.

Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy

D. Groheux, M. Espié, S. Chevret, 2022, Cancers.

Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study.

C. Tournigand, F. Bonnetain, A. Larsen, 2011, The oncologist.

Update : Vinorelbine in the Treatment of non-small-cell Lung cancer

J. Trédaniel, L. Staudacher, C. Hennequin, 2010 .

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas†

R. Korn, J. Tabernero, D. V. Von Hoff, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer

D. Groheux, P. Merlet, M. Espié, 2018, European Journal of Nuclear Medicine and Molecular Imaging.

18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients

D. Groheux, P. Merlet, M. Espié, 2018, Oncotarget.

Prognostic Impact of Stromal Immune Infiltration before and after Neoadjuvant Chemotherapy (NAC) in Triple Negative Inflammatory Breast Cancers (TNIBC) Treated with Dose-Dense Dose-Intense NAC

M. Espié, A. de Roquancourt, S. Giacchetti, 2020, Cancers.

18F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen

Matthieu Resche-Rigon, Marc Espié, Pascal Merlet, 2016, The Journal of Nuclear Medicine.

18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis

D. Groheux, A. Martineau, P. Merlet, 2017, Breast Cancer Research.

Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas.

W. Scheithauer, J. Tabernero, V. Heinemann, 2014 .

Comparison of clinicopathological (CP) features and outcome of breast cancers (BC) in BRCA-mutation carriers patients, with a family history without BRCA-mutation and with sporadic disease.

M. Espié, S. Giacchetti, C. Cuvier, 2018 .

[Targeted agents in the treatment of lung cancer].

L. Staudacher, R. Cohen, L. Teixeira, 2012, Pathologie-biologie.

Vinorelbine thiotepa in metastatic breast cancer: a large real-life retrospective study

M. Espié, S. Giacchetti, C. Cuvier, 2023, Acta oncologica.